Scholarlink

<p>Primary Obesity Surgery Endoluminal 2 (POSE-2) is a minimally invasive endoscopic bariatric procedure. We conducted a systematic review and meta-analysis of one randomized controlled trial (RCT) and three observational studies (N = 210) to evaluate its efficacy, safety, and metabolic outcomes (HbA1c, glucose, cholesterol, triglycerides, LDL, and liver enzymes). Pooled percent total body weight loss (%TBWL) was 13.23% (I<sup>2</sup> = 87%) at 3&#xa0;months, 16.22% (I<sup>2</sup> = 76%) at 6&#xa0;months, and 16.17% (I<sup>2</sup> = 0%) at 12&#xa0;months, showing high heterogeneity early but consistency by 12&#xa0;months. Percent excess weight loss (%EWL) at 12&#xa0;months was 56.95% (I<sup>2</sup> = 0%). HbA1c improved at 6&#xa0;months (SMD = –0.67, p = 0.036, I<sup>2</sup> = 0%), exceeding the minimal clinically important difference (–0.5%), and cholesterol decreased significantly (SMD = –0.25, p = 0.013, I<sup>2</sup> = 0%). Fasting glucose and liver enzymes showed nonsignificant favorable trends with high heterogeneity for ALT/AST (I<sup>2</sup> &gt; 90%). Adverse events were infrequent (2.5–5%), mostly mild, with rare perforations or bleeding. POSE-2 demonstrates promising weight loss and selected metabolic improvements in HbA1c and cholesterol with a favorable short-term safety profile, though evidence is limited to four studies with small sample size, short follow-up, and variable heterogeneity, highlighting the need for larger, longer RCTs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy, Safety, and Metabolic Outcomes of Primary Obesity Surgery Endoluminal 2 (POSE-2) for Obesity: A Systematic Review and Meta-Analysis

  • 期刊论文

  • 发表日期：

    2025年9月29日

查看全文
  • Umar Farooque,
  • Syeda Hafsa Qadri,
  • Ana Beatriz Nardelli da Silva,
  • Andela Malaj,
  • Fnu Aparna,
  • Meer Murtaza,
  • Waseh Ahsan,
  • Arshia Warsi,
  • Dilhana Badurdeen,
  • Aasma Shaukat

摘要

Primary Obesity Surgery Endoluminal 2 (POSE-2) is a minimally invasive endoscopic bariatric procedure. We conducted a systematic review and meta-analysis of one randomized controlled trial (RCT) and three observational studies (N = 210) to evaluate its efficacy, safety, and metabolic outcomes (HbA1c, glucose, cholesterol, triglycerides, LDL, and liver enzymes). Pooled percent total body weight loss (%TBWL) was 13.23% (I2 = 87%) at 3 months, 16.22% (I2 = 76%) at 6 months, and 16.17% (I2 = 0%) at 12 months, showing high heterogeneity early but consistency by 12 months. Percent excess weight loss (%EWL) at 12 months was 56.95% (I2 = 0%). HbA1c improved at 6 months (SMD = –0.67, p = 0.036, I2 = 0%), exceeding the minimal clinically important difference (–0.5%), and cholesterol decreased significantly (SMD = –0.25, p = 0.013, I2 = 0%). Fasting glucose and liver enzymes showed nonsignificant favorable trends with high heterogeneity for ALT/AST (I2 > 90%). Adverse events were infrequent (2.5–5%), mostly mild, with rare perforations or bleeding. POSE-2 demonstrates promising weight loss and selected metabolic improvements in HbA1c and cholesterol with a favorable short-term safety profile, though evidence is limited to four studies with small sample size, short follow-up, and variable heterogeneity, highlighting the need for larger, longer RCTs.